Please login to the form below

Not currently logged in
Email:
Password:

Inflectra

This page shows the latest Inflectra news and features for those working in and with pharma, biotech and healthcare.

Merck & Co's Remicade biosimilar undercuts its US rivals

Merck & Co's Remicade biosimilar undercuts its US rivals

Pfizer and Celltrion's Inflectra (infliximab-dyyb) biosimilar was priced at a 15% discount to Remicade's $30, 000-a-year price tag. ... Sales were flat in 2016 as a whole - Inflectra did not launch until the fourth quarter - but fell 6% in the first

Latest news

  • Biosimilars eat into J&J's Remicade sales Biosimilars eat into J&J's Remicade sales

    competition from Pfizer's Inflectra, Mundipharma's Remsima and Samsung Bioepis' Renflexis/Flixabi. ... Currently only Inflectra is available in the US market - which accounts for two thirds of Remicade sales - but Samsung's biosimilar is expected to be

  • Standing out in a crowd Standing out in a crowd

    Last year it won the first European and US approvals for a biosimilar version of the blockbuster arthritis treatment Remicade (infliximab), which is marketed under the brand names Remsima and Inflectra. ... patients that could have been switched from

  • Pfizer gets FDA panel recommendation for biosimilar EPO Pfizer gets FDA panel recommendation for biosimilar EPO

    If approved, the epoetin alfa biosimilar would be Pfizer's second in the US, after it got the go-ahead from the FDA to sell Inflectra (infliximab-dyyb), a biosimilar of

  • Pfizer’s Remicade biosimilar receives Crohn's trial boost Pfizer’s Remicade biosimilar receives Crohn's trial boost

    Inflectra shown to be similar to originator in data presented at ECCO in Barcelona.  . ... In it Inflectra met its primary end point by demonstrating at six-weeks it was similar to Remicade.

  • J&J pondering future of diabetes device assets J&J pondering future of diabetes device assets

    by the recent launch of a biosimilar competitor - Pfizer's Inflectra - in the US at a 15% discount to the brand.

More from news
Approximately 7 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Innovation in merger control and the impact on the pharmaceutical sector Innovation in merger control and the impact on the pharmaceutical sector

    Specifically, Hospira was selling Inflectra, an infliximab biosimilar used to treat several chronic inflammatory diseases, notably the inflammation of Crohn’s disease, while Pfizer was in an advanced stage of developing

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    This first infliximab biosimilar was developed and manufactured by Celltrion and is marketed by various partners, notably Hospira under the brand name Inflectra and Mundipharma as Remsima. ... Meanwhile, as Europe focuses on the market debuts of

  • Pharma deals in February 2015 Pharma deals in February 2015

    zeta) and Nivestim (filgrastim), and the Remicade copycat  Inflectra (infliximab), the first monoclonal antibody to be approved.

  • Biosimilars: friend or foe for healthcare systems? Biosimilars: friend or foe for healthcare systems?

    The recent approval of Hospira's Inflectra (infliximab) may mark a turning point for biosimilars in Europe. ... products in development (see chart overleaf), with Remsima/Inflectra the only biosimilar mentioned specifically by name. .

  • Pharma deals during September 2013 Pharma deals during September 2013

    This deal comes in the same month as the EU approved Hospira's Inflectra (infliximab), as a direct competitor to reference medical product Remicade (2012 European sales of more than $2bn). ... This is Europe's first biosimilar mAb therapy. Inflectra has

More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • The Biosimilar Challenge

    These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon. .

  • Infographic: RA Perceptions

    Physicians predict a four-fold increase in their use of Hospira’s Inflectra and Celltrion’s Remsima.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics